Thyroid hormones influence the function of many organs and mediate their diverse actions through two types of thyroid hormone receptors, TR␣ and TR␤. Little is known about effects of ligands that preferentially interact with the two different TR subtypes. In the current study the comparison of the effects of the novel synthetic TR␤-selective compound GC-1 with T 3 at equimolar doses in hypothyroid mice revealed that GC-1 had better triglyceride-lowering and similar cholesterol-lowering effects than T 3 . T 3 , but not GC-1, increased heart rate and elevated messenger RNA levels coding for the I f channel (HCN2), a cardiac pacemaker that was decreased in hypothyroid mice. T 3 had a larger positive inotropic effect than GC-1. T 3 , but not GC-1, normalized heart and body weights and messenger RNAs of myosin heavy chain ␣ and ␤ and the sarcoplasmic reticulum adenosine triphosphatase (Serca2). Additional dose-response studies in hypercholesteremic rats confirmed the preferential effect of GC-1 on TR␤-mediated parameters by showing a much higher potency to influence cholesterol and TSH than heart rate. The preferred accumulation of GC-1 in the liver vs. the heart probably also contributes to its marked lipid-lowering effect vs. the absent effect on heart rate. These data indicate that GC-1 could represent a prototype for new drugs for the treatment of high lipid levels or obesity. (Endocrinology 141: [3057][3058][3059][3060][3061][3062][3063][3064] 2000) 
4.5 ϫ GC-1 equals 8.0 ng/g BW⅐day, 9 ϫ GC-1 equals 16.2 ng/g BW⅐day, 4.5 ϫ T 3 equals 15.8 ng/g BW⅐day, and 9 ϫ T 3 equals 31.5 ng/g BW⅐day. The 1 ϫ dose is equivalent to 5.38 nmol/kg, the 4.5 ϫ dose to 24 .67 nmol/kg, and the 9 ϫ dose to 49.33 nmol/kg. The effect of each dose was studied after 4 weeks of daily ip injection in groups of six agematched mice. One week before the start of the injection mice were made hypothyroid by administration of a special iodine-deficient mouse chow containing the thyroid hormone biosynthesis inhibitor 5-propyl-2-thiouracil (0.15%; Harlan Teklad, Madison, WI). Mice were kept on this hypothyroid regimen during the study. One hypothyroid group of seven mice remained untreated. A group of six untreated euthyroid mice fed standard mouse chow was used as the control group. Electrophysiological measurements were performed in all mice at the end of the treatment period. Hemodynamic measurements were performed in control and hypothyroid mice treated with 1 ϫ GC-1 and 1 ϫ T 3 . Serum for lipid measurement and cardiac tissue for determination of the messenger RNA (mRNA) levels of certain proteins were collected from all mice at the end of the study. Each group consisted of male and female mice, aged of 10 -15 weeks.
In vivo hemodynamic measurements. Heart rate was calculated from electrophysiological tracings. Mice were lightly sedated with ketamine (0.033 mg/g BW) and pentobarbital (0.033 mg/g BW) and restrained (17) . Four needles were placed sc on each limb close to the trunk, and 6 min after injection of sedatives an electrocardiogram (ECG) was obtained. Heart rate was calculated from the RR interval. For measurement of in vivo hemodynamics, mice were anesthetized with a mixture of ketamine (0.1 mg/g BW) and xylazine (0.007 mg/g BW) and placed under a dissecting microscope (18) . ECG electrodes were connected to the limbs, and the body temperature was monitored with an anal temperature probe and kept at 37 C. The animals were intubated and ventilated with room air. A bilateral vagotomy was performed. The right jugular vein and right carotid artery were cannulated with polyethylene catheters, and the carotid line was connected to a pressure gauge. Arterial pressure was measured at this time point. Next, a left-sided thoracotomy was performed. The pericardium was opened, and a high fidelity pressure transducer (1.8 French, Millar Instruments, Houston, TX) was inserted into the left atrium and advanced into the left ventricle. Continuous left ventricular (LV) pressure, differential LV pressure, aortic pressure, and ECG were recorded on a personal computer. After recording the measurements, increasing doses of isoproterenol were infused through the venous line (5, 50, 500, and 1000 ng). The following parameters were analyzed: heart rate (HR), carotid arterial pressure, LV end-systolic pressure (LVESP), and the maximum values of LV pressure derivatives (dP/dt max , dP/dt min ). Effects of isoproterenol on hemodynamic parameters were analyzed 45-60 sec after drug administration.
Northern blot analysis. Messenger RNA levels for sarcoplasmic reticulum calcium adenosine triphosphatase (Serca2), myosin heavy chain ␣ (MHC␣), MHC␤, and the hyperpolarization-activated cyclic nucleotidegated channel 2 (HCN2) were determined. RNA was isolated from myocardial tissue by a guanidinium thiocyanate method (19) , and polyadenylated RNA was obtained using an oligo(deoxythymidine) kit (QIAGEN, Chatsworth, CA). mRNA was separated on a 1% agarose gel and transferred to a nylon membrane. A 1.6-kb fragment of the 5Ј-end of the rat Serca2 complementary DNA, a 224-bp fragment of the second exon of mouse HCN2 complementary DNA, and oligonucleotides specific for the rat MHC␣ and rat MHC␤ were used to make 32 P-labeled probes (Multiprime DNA labeling systems, Amersham Pharmacia Biotech, Aylesbury, UK). Radioactivity was assessed on a blue film (Eastman Kodak Co., Rochester, NY), and the resulting image was quantified with Image 1.61 software.
Measurements of cholesterol and triglycerides in mice.
Blood was collected from all mice at the end of the study; the serum was separated by centrifugation and immediately frozen in liquid nitrogen. Triglycerides and cholesterol were measured by enzymatic methods (Roche, Basel, Switzerland).
Statistical analysis. Parameters in control, hypothyroid mice and in hypothyroid mice treated with different doses of GC-1 and T 3 were analyzed by ANOVA and Fisher's post-hoc tests. P Ͻ 0.05 was assumed significant. Data are given as the mean Ϯ sem.
Dose-response studies in hypercholesteremic rats
Male Sprague Dawley rats (Harlan Sprague Dawley, Inc.), weighing 300 -400 g, were used for this study. The rats were fed a diet containing 1.5% cholesterol and 0.5% cholic acid (Harlan Teklad Rodent Chow, Madison, WI) for 2 weeks before drug treatment and for the entire course of the study. The rats were given via oral gavage either vehicle (n ϭ 6; a separate vehicle group was used for the T 3 -treated group and the GC-1 treated group, also n ϭ 6) or the following drug treatment groups: 1.54 -924 nmol/kg⅐day T 3 (n ϭ 5/group) or 46.2-2920 nmol/kg⅐day GC-1 (n ϭ 5/group). The doses correspond to 1.0 -601.5 ng/g⅐day T 3 and 15.2-958.9 ng/g⅐day GC-1. The vehicle or drugs were administered once per day for 7 days. Vehicle consisted of 5% cremaphor, 5% ethanol, 10% m-pyrol, and 80% water. The animals were weighed each day before drug administration. After 7 days, the rats were anesthetized using 40 mg/kg pentobarbital sodium, ip, and the heart rates were measured by ECG (Gould Instruments, Valley View, OH). A 3-ml blood sample was taken via the inferior vena cava for each animal. The blood samples were centrifuged at 2000 rpm for 20 min, and the plasma was used for cholesterol, triglyceride, and TSH measurements. Plasma cholesterol measurement was performed using a Cobas Mira S analyzer (Roche, Indianapolis, IN). Plasma TSH was measured using a RIA kit designed for rat TSH (Amersham Pharmacia Biotech, Arlington Heights, IL).
The doses chosen were based on the lowest dose of T 3 (1 g/kg⅐day or 1.54 nmol/kg⅐day). For the purpose of comparison between GC-1 and T 3 , all doses are denoted as nanomoles per kg/day. Increasing doses of T 3 or GC-1 were then given in half-log increments.
Determination of T 3 , T 4 , and GC-1 levels in plasma and tissues
Male Sprague Dawley rats were anesthetized with 30 mg/kg pentobarbital, ip. Either T 3 or GC-1 (10 mol/kg) was injected directly into the right jugular vein (n ϭ 3/group). Plasma and tissue samples were collected 1 h after treatment. For various tissues, samples were weighed and homogenized with 3 vol deionized water. For T 3 and T 4 assays, 100-l samples were treated with 250 l acetonitrile containing 100 ng/ml internal standard (IS-I). For GC-1 assays, 25-l samples were treated with 50 l acetonitrile containing 100 ng/ml internal standard (IS-II). After centrifugation to remove precipitated proteins, the clear supernatant was dried with nitrogen in silanized glass vials and then reconstituted with 50 l acetonitrile-water (50:50). Due to endogenous production of T 3 and T 4 hormones, standard curve and quality control samples for T 3 and T 4 measurements were prepared using acetonitrilewater (50:50) mixture in the same fashion as for the tissue treatment. A 10-l aliquot of the reconstituted solution was analyzed by liquid chromatography/tandem mass spectrometry.
Sample analysis was performed using a Shimadzu LC system (Shimadzu Scientific, Kyoto, Japan) with an Inertsil (MetaChem Technologies, Torrance, CA) ODS-2 HPLC column (2 ϫ 50 mm, 5 m) interfaced to a Micromass Quattro (Micromass UK Limited, Manchester, UK) tandem mass spectrometer. The mobile phases consisted of 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). With a flow rate of 0.3 ml/min, a linear gradient was started from 95% A/5% B to 5%A/95% B over 2.5 min and was held at 5% A/95% B for an additional 1.5 min. The mobile phase was then returned to initial conditions, and the column was reequilibrated for 2 min. The total analysis time was 6 min. MS/MS conditions were as followings: electrospray ionization; ultra high purity nitrogen as nebulizing gas (100 liters/h) and desolvation gas (900 liters/ ϩ species for T 3 , T 4 , GC-1, and internal standards were selected in MS1 and collisionally dissociated with argon at a pressure of 1.5 ϫ 10 Ϫ3 T to form specific product ions that were subsequently monitored by MS2. Instrument parameters for each compound are shown in Table 1 .
Results

Body and heart weights
Hypothyroid mice showed typical evidence of severe thyroid hormone deficiency (Table 2) ; body weight, heart weight, and heart weight to body weight ratio (HW/BW ratio) were markedly decreased compared with those in euthyroid age-matched mice. Treatment of hypothyroid mice with 1 ϫ T 3 , 4.5 ϫ T 3 , and 9 ϫ T 3 increased body weight, heart weight, and HW/BW ratio. Treatment with 1 ϫ GC-1 and 4.5 ϫ GC-1 did not increase body weight or HW/BW ratio. At the 9 ϫ GC-1 dose, heart weight was significantly increased, and there was a trend (albeit insignificant) for an increase in body weight. No toxic effects were observed in mice treated with GC-1. The appearance and behavior of GC-1-treated mice were similar to those of T 3 -treated mice.
Cardiac effects of GC-1 and T 3 in mice
Heart rate in hypothyroid mice (Table 3) was markedly decreased to 335 Ϯ 21 beats/min from a heart rate in control mice of 472 Ϯ 26 beats/min (P Ͻ 0.001 control vs. hypothyroid). Whereas treatment with 1 ϫ T 3 lead to an increase to 502 Ϯ 21 beats/min (P Ͻ 0.001 hypothyroid vs. 1 ϫ T 3 -treated), mice treated with the equimolar amount of 1.8 ng/g BW GC-1 (1 ϫ GC-1) retained a low heart rate of 358 Ϯ 28 beats/ min (P Ͻ 0.01 control vs. 1 ϫ GC-1-treated). Higher equimolar doses of the compounds let to similar increases in heart rate; 4.5 ϫ T 3 and 4.5 ϫ GC-1 increased heart rates to 536 Ϯ 24 and 527 Ϯ 35 beats/min, respectively, and treatment with 9 ϫ T 3 and 9 ϫ GC-1 resulted in heart rates of 584 Ϯ 28 and 570 Ϯ 31 beats/min, respectively. All other hemodynamic parameters measured, systolic and diastolic arterial pressure (P a sys and P a dias ), end-systolic left ventricular pressure (LVESP), and maximum speeds of contraction (dP/dt max ) and relaxation (dP/dt min ), were also severely decreased in hypothyroid mice (Table 3) . 1 ϫ GC-1 showed a positive inotropic effect (Figs. 2 and 5) by increasing dP/dt max to 4424 Ϯ 510 from 2945 Ϯ 273 mm Hg/sec in hypothyroid mice (P Ͻ 0.05 hypothyroid vs. 1 ϫ GC-1-treated), although this was less than the effect of 1 ϫ T 3 that resulted in a dP/dt max of 6224 Ϯ 888 mm Hg/sec (P Ͻ 0.05 1 ϫ T 3 -treated vs. 1 ϫ GC-1-treated). Treatment with 1 ϫ T 3 , but not with 1 ϫ GC-1, also increased P a sys , P a dias , LVESP, and dP/dt min (P Ͻ 0.05 hypothyroid vs. 1 ϫ T 3 -treated). The positive inotropic response was assessed by the increase in arterial pressure and the maximal speed of contraction after administration of isoproterenol. Administration of increasing doses of isoproterenol iv resulted in positive inotropic effects in all groups. The hemodynamic effects of 500 ng isoproterenol are presented as the percent increase from the basal level; arterial pressure increased from basal levels in control, hypothyroid, 1 ϫ T 3 -treated, and 1 ϫ GC-1-treated mice by 25 Ϯ 5%, 23 Ϯ 2%, 25 Ϯ 5%, and 36 Ϯ 9% respectively, dP/dt max increased by 16 Ϯ 6%, 25 Ϯ 11%, 14 Ϯ 5%, and 17 Ϯ 9% respectively. These data show that the sympathetic responses of the hypothyroid, 1 ϫ GC-1, and 1 ϫ T 3 groups were not different from that of the control group. 
Hypothyroid mice were treated with 3.5 ng/g BW T 3 (1 ϫ T 3 ), which was a dose assumed to restore euthyroidism, with the equimolar amount of 1.8 ng/g BW GC-1 (1 ϫ GC-1), and with higher doses of both compounds (4.5 ϫ T 3 , 9 ϫ T 3 , 4.5 ϫ GC-1, 9 ϫ GC-1). T 3 -treated mice showed increased body weight, heart weight, and heart weight to body weight ratios (HW/BW ratio) at all doses. 1 ϫ GC-1 and 4.5 ϫ GC-1 did not increase body weight, heart weight, or heart weight to body weight ratio. Only 9 ϫ GC-1 treatment led to an increase in heart weight.
a P Ͻ 0.0001 vs. hypothyroid. b P Ͻ 0.05 vs. hypothyroid. All measured hemodynamic parameters were severely decreased in hypothyroid mice. This decrease was completely reversed by 1 ϫ T 3 , which normalized heart rate, arterial pressure, LVESP, dP/dt max , and dP/dt min . 1 ϫ GC-1 had a differential effect on the hemodynamic system; it led to an increase in dP/dt max , but did not change heart rate.
a P Ͻ 0.05, hypothyroid vs. control mice. b P Ͻ 0.05, 1 ϫ T 3 -treated vs. hypothyroid mice. c P Ͻ 0.05, 1 ϫ GC-1 treated vs. hypothyroid mice.
Levels of mRNAs coding for cardiac proteins
Cardiac tissue of hypothyroid mice showed changes in MHC isoform expression typically seen in hypothyroidism (20) , with high mRNA levels of MHC␤ and almost no MHC␣ mRNA. Treatment of hypothyroid mice with 3.5 ng/g BW T 3 (1 ϫ T 3 ) completely reversed the pattern of MHC isoform expression; control MHC␣ mRNA levels were restored, and MHC␤ mRNA was no longer detected. In contrast, treatment with 1 ϫ GC-1 did not increase MHC␣ expression, and the decrease in MHC␤ mRNA was smaller than that in 1 ϫ T 3 -treated mice. Treatment with 9 ϫ GC-1 increased MHC␣ mRNA to euthyroid levels, but MHC␤ mRNA was still detectable (Figs. 3 and 5) .
Hypothyroidism resulted in a 70% decrease in mRNA for the sarcoplasmic calcium pump protein (Serca2) and almost completely abolished mRNA for the cardiac pacemaker channel HCN2. Changes in Serca2 were fully reversed in mice treated with T 3 at all doses (P Ͻ 0.05, T 3 treated vs. hypothyroid; T 3 treated not different from control), whereas treatment with GC-1 restored Serca2 mRNA levels only at the highest dose of 9 ϫ GC-1. mRNA levels for HCN2 were fully restored by treatment with 1 ϫ T 3 , and further increased over euthyroid levels with treatment with 4.5 ϫ T 3 and 9 ϫ T 3 respectively. GC-1-treated mice had decreased HCN2 levels with 1 ϫ GC-1 and 4.5 ϫ GC-1 treatments, and only treatment with 9 ϫ GC-1 restored normal HCN2 levels (Figs. 3  and 5 ).
Lipid-lowering effects in mice
Beneficial effects on the lipid profile were equal or greater in GC-1-treated mice than in T 3 -treated mice (Figs. 4 and 5) ; cholesterol levels were elevated in hypothyroid mice to 165 mg/dl compared with 74 Ϯ 3 mg/dl in euthyroid mice (P Ͻ 0.0001). Both T 3 and GC-1 treatment at all doses decreased cholesterol to normal levels. Triglycerides were elevated in hypothyroid mice to 126 Ϯ 15 mg/dl compared with 70 Ϯ 15 mg/dl in euthyroid mice (P Ͻ 0.05). GC-1 reestablished normal triglyceride levels at all doses, whereas T 3 treatment failed to decrease triglyceride levels from the elevated hypothyroid levels.
Dose-responses to GC-1 and T 3 in rats
The effects of T 3 or GC-1 on plasma cholesterol, heart rate, and plasma TSH are shown in Fig. 6 . These data are shown as the percent change for each of these parameters relative to their respective vehicle-treated group values. Plasma cholesterol was reduced by T 3 and GC-1 in a dose-dependent manner. The vehicle-treated group values for cholesterol were 187 Ϯ 25 and 180 Ϯ 24 mg/dl for the T 3 and GC-1 studies, respectively. For the purpose of comparison, ED 50 values for cholesterol reduction are shown in Table 4 . ED 50 was defined as the dose of drug causing a 50% reduction in cholesterol compared with the vehicle-treated group value, and this was chosen because it was approximately half of the maximal effect (80 -90% reduction). As shown in this table, the ED 50 for cholesterol lowering was 12-fold lower with T 3 than with GC-1. For the T 3 -treated group, cholesterol was significantly reduced (compared with vehicle, P Ͻ 0.05) starting at the 15.4 nmol/kg⅐day dose. For GC-1, significant cholesterol lowering vs. that in vehicle-treated animals was seen at the 154 nmol/kg⅐day dose and higher doses (P Ͻ 0.05).
T 3 increased heart rate in a dose-dependent manner, whereas GC-1 had little effect on heart rate within the dose range tested (Fig. 6) . Heart rates were 364 Ϯ 9 and 378 Ϯ 8 beats/min for the vehicle-treated groups for the T 3 and GC-1 studies, respectively. Heart rate was increased by T 3 , and significance was noted starting at the 46.2 nmol/kg⅐day dose (P Ͻ 0.05 vs. vehicle). No significant changes in heart rate FIG. 2. In vivo hemodynamic measurements. Hypothyroid mice showed markedly decreased heart rate and maximum speed of contraction (dP/dt max ) compared with control mice. Heart rate increased in mice treated with 1 ϫ T 3 (3.5 ng/g BW), but not in mice treated with equimolar amounts of GC-1 (1.8 ng/g BW). Both compounds had a positive inotropic effect on dP/dt max . This positive inotropic effect was higher in 1 ϫ T 3 -treated mice, which had increased dP/dt max , than in hypothyroid mice and 1 ϫ GC-1-treated mice.
FIG. 3.
Northern blots of messenger RNA of MHC␣, MHC␤, sarcoplasmic calcium ATPase (Serca2), and hyperpolarization-activated cyclic nucleotide-dependent channel (HCN2) and 28S in cardiac tissue. The decrease in MHC␣ and the increase in MHC␤ in hypothyroid mice were fully compensated in mice treated with 1 ϫ T 3 (3.5 ng/g BW), 4.5 ϫ T 3 , and 9 ϫ T 3 . Treatment of hypothyroid mice with 1 ϫ GC-1 did not decrease MHC␤ or increase MHC␣ compared with hypothyroid levels. Higher doses of GC-1 reversed MHC␣ mRNA to control levels, but MHC␤ mRNA was undetectable even with the highest dose of GC-1 (16.2 ng/g BW, 9 ϫ GC-1). Serca2 mRNA, which was decreased in hypothyroid mice, was fully restored by treatment with any T 3 dose, whereas GC-1 only increased Serca2 mRNA at 16.2 ng/g BW. HCN2 mRNA levels, which were severely decreased in hypothyroid mice, were restored by T 3 and increased further with higher T 3 doses. In contrast, treatment with 1 ϫ GC-1 did not increase levels of HCN2 mRNA, and only 9 ϫ GC-1 reconstituted normal HCN2 levels. 28S was used to control for equal loading.
were observed for GC-1 with the doses used in this study. Potencies for changes in heart rate were expressed as ED 15 , which is the dose causing a 15% increase in heart rate relative to the time-matched vehicle group value. The ED 15 was chosen because a 10 -15% increase in heart rate is viewed as being the lower end of clinically relevant changes in heart rate. In addition, the potency ratios for ED 15 (heart rate)/ ED 50 (cholesterol) are shown in Table 4 . The ratio was approximately 10-fold higher for GC-1 compared with T 3 , suggesting that GC-1 was significantly more selective for lowering cholesterol than it is for causing tachycardia.
TSH was reduced by both GC-1 and T 3 in a dose-dependent manner, although T 3 was approximately 20-fold more potent than GC-1. T 3 significantly reduced TSH starting at the 4.62 nmol/kg⅐day dose, whereas GC-1 did so starting at the 154 nmol/kg⅐day dose (P Ͻ 0.05 compared with their respective vehicle group values). The potency for TSH suppression was expressed as ED 30 , because the maximal percent suppression was approximately 60% in these animals. As TSH suppression and cholesterol lowering are both presumably TR␤-mediated effects, it would be expected that the potency ratios for TSH vs. cholesterol lowering should be similar for T 3 and GC-1. GC-1 was slightly more selective for lowering cholesterol than was TSH, although this difference was only 2-fold, which is not pharmacologically significant.
Tissue distribution of GC-1 and T 3
Measurements of GC-1 and T 3 in plasma and tissues revealed distinct differences in their organ distributions ( Table  5 ). The tissue to plasma ratios in the liver were similar for GC-1 and T 3 (2.09 Ϯ 0.53 and 5.86 Ϯ 1.93, respectively). In contrast the tissue/plasma ratio in the heart was 30 times higher for T 3 (3.61 Ϯ 0.69 ng/g) than for GC-1 (0.12 Ϯ 0.002 ng/g). Absolute values for plasma levels were 75 times different (3188 Ϯ 445 ng/ml for T 3 and 42 Ϯ 8 ng/ml for GC-1).
Discussion
Recently accumulated evidence firmly indicates that binding of T 3 to products of the c-erbA␣ gene (TR␣1) vs. those of the c-erbA␤ gene (TR␤1) or its splice variant TR␤2 leads to distinct thyroid hormone effects (21, 22) . It is therefore of interest to develop new T 3 agonists and antagonists with preferred binding and action through the various TR isoforms and explore influences of these analogs on specific thyroid hormone-responsive physiological functions. 3 and GC-1 on blood lipid levels. Cholesterol and triglyceride levels were increased in hypothyroid mice. Treatment of hypothyroid mice with T 3 and GC-1 decreased cholesterol to euthyroid levels at all doses. GC-1 also lowered triglycerides to control levels, whereas T 3 had no effect on triglyceride levels at any dose. GC-1 was more effective at lowering triglyceride levels than treatment with the equimolar dose of T 3 .
FIG. 4. Effects of T
FIG. 5. Differential effects of 1 ϫ GC-1 on cardiac activity and lipid levels. To compare the effects of treatment with 1 ϫ T 3 (3.5 ng/g BW) and equimolar amounts of GC-1 (1.8 ng/g BW, 1 ϫ GC-1) on different parameters in hypothyroid mice, the effect was expressed as a percentage of the parameter's change from the hypothyroid to the euthyroid level, which was defined as 100%. This comparison shows that 1 ϫ T 3 treatment normalized all cardiac parameters to the euthyroid level, whereas treatment with 1 ϫ GC-1 changed only dP/dt max significantly and did not increase any of the other cardiac parameters. In contrast, treatment of hypothyroid mice with 1 ϫ GC-1 lowered elevated cholesterol and triglyceride levels, whereas 1 ϫ T 3 treatment normalized only cholesterol levels, but not triglyceride levels.
Described in this report are the effects of the T 3 analog GC-1, which exhibits similar binding affinity and actions in cell culture as T 3 for the TR␤1 subtype, but approximately 10 times weaker binding and actions in cell culture for the TR␣1 subtype (15) . Upon administration of T 3 at a dose that largely restored a euthyroid status (3.5 ng/g BW, defined as 1 ϫ T 3 ) and equimolar amounts of GC-1 (1.8 ng GC-1/g BW, defined as 1 ϫ GC-1), distinct differences in the responses of specific thyroid hormone-responsive parameters were noted. Thus, 1 ϫ GC-1 lowered cholesterol levels to the euthyroid range, as did administration of 1 ϫ T 3 . Triglyceride levels were lowered significantly with GC-1 compared with T 3 , which exerted no significant effect on triglyceride levels. 1 ϫ GC-1 did not increase heart rate from the hypothyroid level, but T 3 at this dose significantly increased heart rate and restored it to the normal euthyroid level. The mRNA coding for the pacemaker channel HCN2, which was severely decreased in hypothyroid mice, was restored by 1 ϫ T 3 to control levels and further increased with higher T 3 doses, whereas 1 ϫ GC-1 did not affect HCN2, and only higher GC-1 doses restored mRNA HCN2 levels. These effects of T 3 and GC-1 on HCN2 paralleled their effects on heart rate. Restoration to control values by 1 ϫ T 3 , but not by 1 ϫ GC-1, was also seen for mRNAs of MHC␣, MHC␤, and Serca2 and for body weight, heart weight, and HW/BW ratio. Cardiac contractility was increased by 1 ϫ GC-1 and 1 ϫ T 3 , although this effect was larger and included more parameters with 1 ϫ T 3 .
The potential mechanism underlying this and other differential responses between GC-1 and T 3 could be linked to differences in TR␤ isoform distribution in specific organs. Findings by other investigators have shown that TR␤ receptors are the predominant isoform in the liver, accounting for 80% of T 3 receptor binding (23) . In addition, the T 3 -mediated lowering of cholesterol levels is most likely due to an elevated clearance rate of cholesterol mediated by increased expression of hepatic low density lipoprotein receptors (24) and an increase in specific lipid-lowering liver enzymes (6, 25, 26) . The strong effect of GC-1 on lowering cholesterol, which is equal to that of T 3 , and the even more enhanced effect of GC-1 on lowering triglyceride levels, which exceeds the effect of T 3 , is therefore compatible with a TR␤-preferred action of GC-1. In contrast to the liver, close to half of the T 3 receptors in the heart are of the TR␣1 subtype (23) . The target genes of thyroid hormone effects on the heart rate are not known, although HCN2 and HCN4 are possible candidates. As mentioned previously, mice with deletion of the TR␣ (12), but not the TR␤ (14), receptor have marked bradycardia. The absence of GC-1 effects on increasing heart rate from the hypothyroid value is compatible with the previous finding that the EC 50 on TR␣1 for GC-1 is approximately 10 times greater than that of T 3 , and T 3 action on heart rate is mediated through TR␣1. In contrast, a T 3 dose of 3.5 ng/g BW returned heart rate from a decreased hypothyroid rate to the normal euthyroid range. These differential effects of T 3 vs. GC-1 on heart rate are compatible with selective TR␤ actions of GC-1. However, in this context we cannot exclude tissue-selective differences in the uptake of the various compounds as contributors to the differential responses.
Recently, the gene coding for the cardiac pacemaker channel I f , which appears to play an essential role in setting the heart rate, has been cloned (27, 28) . This hyperpolarizationactivated inward rectifier channel conducts the monovalent cations potassium and sodium at a 4:1 ratio. This channel has been termed hyperpolarization-activated cyclic nucleotideregulated (HCN) channel. Four isoforms of it occur in the brain (HCN1-HCN4) (27, 28) . Two of these, HCN2 and HCN4, are expressed in the heart, with a marked predominance of HCN2 (Gloss, B., and W. H. Dillmann, unpublished observations). As the expression of this gene might be involved in thyroid hormone effects on heart rate, we quantitated the response of HCN2 to T 3 and GC-1 and found a response in line with that of heart rate. HCN2 mRNA does not significantly increase upon treatment with 1 ϫ GC-1, in contrast to treatment with 1 ϫ T 3 , which results in elevated HCN2 mRNA levels compared with euthyroid levels. It appears therefore quite likely that the discrepant heart rate and HCN2 responses to T 3 and GC-1 may indicate a cause-effect relationship between the heart rate and the level of expression of the HCN2 channel. Thus, HCN2 may be a major target for thyroid hormone regulation of the heart rate. In line with the effects on heart rate are other markedly smaller effects of GC-1 vs. T 3 on other cardiac parameters. This includes the finding that 1 ϫ GC-1 has no significant effect on heart weight and mRNAs coding for proteins related to cardiac FIG. 6 . Effect of 7 days of treatment with GC-1 or T 3 on plasma cholesterol, TSH, and heart rate in cholesterol-fed rats. Cholesterol and TSH were reduced by both compounds in a dose-dependent manner. T 3 caused a dose-dependent increase in heart rate within the cholesterol-lowering dose range, whereas GC-1 had no effect.
contraction, such as MHC␣, MHC␤, and Serca2. It is of interest to note that the first derivative of the rise in systolic pressure, dP/dt max , significantly increased by treatment with 1 ϫ GC-1, although this effect was smaller than that with 1 ϫ T 3 treatment. Some specific cardiac functions, such as dP/dt max , show a partial response to a TR␤-preferred agent.
Whereas the GC-1-induced lowering of cholesterol shows a similar response to T 3 at doses of 1.8, 8.1, and 16.2 ng/g BW, other responses differ. Thus, GC-1-induced lowering of triglyceride levels is more efficient at all doses compared with T 3 . In contrast, other parameters, such as body weight or HW/BW ratio, showed no change from the hypothyroid level at any GC-1 dose, in contrast to T 3 , which resulted in marked and progressive increases in these parameters. The mechanisms underlying these discrepant T 3 vs. GC-1 responses are currently unclear. The GC-1 effect on heart weight, which only occurs at high GC-1 doses, is in line with a significantly diminished GC-1 effect on parameters such as heart rate and reversal of MHC␣ RNA levels and MHC␤ mRNA levels compared with T 3 . In addition, the T 3 -induced increase in body weight was already maximal at doses of 3.5 ng/g BW and did not further increase at higher T 3 doses. It is unlikely that the decreased response of heart weight or MHC␣ mRNA levels of GC-1-treated mice is due simply to a much weaker thyromimetic action than T 3 , as this would not explain the equivalent effects of GC-1 and T 3 on cholesterol levels and the greater effects of GC-1 than T 3 on triglyceride levels. Results from mice with deletion of TR␣ vs. TR␤ clearly indicate that for some effects T 3 can exert a similar influence, being bound to either TR␣1 or TR␤1, and the different TR isoforms can exert functional cross-coverage for each other. In contrast, other effects can only be fully mediated by T 3 bound to either the TR␣ or the TR␤. Another mechanism that has to be considered for differential effects of GC-1 is the difference in tissue distribution; tissue/plasma ratios of T 3 are similar for heart and liver, whereas the tissue/ plasma ratio of GC-1 for the liver is 17 times higher than that for the heart. This difference in tissue distribution ratio could contribute to a higher stimulation of hepatic effects such as lipid lowering by GC-1 without increasing the heart rate. This observation implies that organ-specific distribution contributes to the effect of this new thyroid hormone analog. Much lower absolute levels of GC-1 than of T 3 in plasma and tissues also indicate that GC-1 may be more rapidly metabolized than T 3 . Details of T 3 vs. GC-1 pharmacokinetics need to be clarified by an in-depth study; however, it may be that the tissue-selective thyromimetic effects of GC-1 arise from a combination of selective tissue uptake and selective activation of TR 127.
The comparative effects of GC-1 and T 3 on rats were determined to show the relationship between heart rate vs. cholesterol and TSH vs. cholesterol. This was performed in rats because of the greater reliability of heart rate and TSH measurements in this species. As TSH and cholesterol lowering are both thought to be primarily due to TR␤ activation (12, 14) , the potency ratios for these two plasma parameters should be similar for T 3 and GC-1. The ED 30 (TSH)/ED 50 (cholesterol) potency ratios were similar for GC-1 and T 3 , which is consistent with them being mediated by the same receptor subtype. GC-1 was significantly more selective for cholesterol lowering compared with its tachycardic potency. The selectivity was more than 15-fold, and this may be conservative, as we could not observe significant tachycardia even at high doses. These data are consistent with the TR␤ binding selectivity for this compound (15) . Tachycardia is thought to be primarily due to TR␣ stimulation, and our results are consistent with this hypothesis; however, selective tissue uptake may also play a role, as mentioned previously.
Although GC-1 is relatively selective for TR␤, it has a slightly weaker binding affinity (2-fold less potent) compared with T 3 . The differences in potency for cholesterol and TSH suppression were on the order of 10-to 20-fold less potent for GC-1. These differences in potency of TR␤-mediated effects of GC-1 and T 3 were not observed in mice. Cholesterol levels were similarly lowered by equivalent T 3 and GC-1 doses, and GC-1 was even more effective in lowering triglycerides. The rats were euthyroid and had only elevated cholesterol levels, so an influence on triglyceride lowering could not be assessed. The effects of GC-1 and T 3 on cholesterol levels in mice were maximal at the 1ϫ doses; thus, a difference of potency for this parameter might have become apparent at lower GC-1 and T 3 doses. T 3 and GC-1 were administered orally to rats to determine whether the in vitro EDs are expressed as the dose lowering cholesterol by 50%, that lowering TSH by 30%, or that increasing heart rate by 15%. Values for the GC-1 or T 3 dose are expressed as nanomoles per kg/day. TABLE 5. Tissue levels (nanograms per ml) and tissue/plasma ratios (T/P ratio; nanograms per g) of T 3 and GC-1 in rats T 3 T/P ratio, T 3 GC-1 T/P ratio, GC-1 (T/P ratio GC-1)/ (T/P ratio T 3 ) The relation of the T/P ratio of GC-1 to the T/P ratio of T 3 was 10 times lower in the heart than in the liver. Tissue was harvested 1 h after iv injection of 10 mol/kg T 3 or GC-1.
a The detection limit for GC-1 was approximately 1 ng/ml. selectivity could be observed when administered in the manner in which patients will be treated. The selectivity should not be affected by differences in oral absorption, although the apparent potency could certainly be affected. The results clearly showed that therapeutic cholesterol-lowering activity was observed for GC-1 without concomitant tachycardia, unlike T 3 ; therefore the in vitro studies correctly predicted the selectivity observed in vivo. Previous reports (7, 8) of thyroid hormone analogs have indicated that some thyroid hormone analogs can lead to lipid lowering without significant cardiac effects. A differential effect on the heart was observed for the compound 3,5-diiodothyropropionic acid, which increased cardiac contractility without increasing heart rate and MHC isoform expression (29) . The actual mechanism of action of this compound is also not clear, as 3,5-diiodothyropropionic acid differs in several aspects from the chemical structure of thyroid hormones, and its binding to thyroid receptors was not studied.
There has been extensive interest in using thyroid hormones for treating a variety of indications, including weight loss, lowering plasma lipid levels, and treatment of hypothyroid states in the elderly. Unfortunately, the use of thyroid hormones for these indications has been limited, predominantly by the fact that the compounds have adverse effects on the heart, particularly on heart rate and rhythm. The findings in the current study and in some previous reports (7, 8) indicate that lowering of cholesterol without a significant increase in heart rate is possible. Our report shows that a compound such as GC-1 has TR␤-selective actions, with over 14 times greater potency on lowering cholesterol and TSH levels than on heart rate, with similar or greater effects than T 3 on triglyceride levels and diminished effects relative to T 3 on weight gain and heart rate. These findings provide further support for the idea that compounds with such selectivity can be generated. Whereas the mechanism for these in vivo actions is not fully understood and may involve a combination of selective tissue uptake and selective TR subtype activation, the results suggest that compounds with properties similar to GC-1 may be useful therapeutic agents for the treatment of a variety of thyroid hormone-related metabolic disorders.
